Skip to content
DataLookout
Menu

INSTANT-2NCT07842185

A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke

StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Nov 19, 2026 to Dec 19, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 66 words
    • Enrollment reduced: 1482 → 1192 participants
    • Interventions modified
    • Trial arms changed: 3 → 2
    • Study title shortened, about 2 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Proportion of patients with mRS 0-1 at 90 days
Timeframe: 90 days after randomization

Secondary (5)

mRS score at 90 days
EQ-5D-5L score at 90 days
Proportion of patients with mRS 0-2 at 90 days
Proportion of patients with mRS 0-3 at 90 days
Proportion of early neurological improvement

Arms and interventions

Arm A: Tirofiban 24-hour groupExperimental

Arm A: Patients receive tirofiban for 24 hours after intravenous thrombolysis.

Arm B: Tirofiban 48-hour groupExperimental

Arm B: Patients receive tirofiban for 48 hours after intravenous thrombolysis.

Drugs: Tirofiban Injection

Sites

10 sites in 1 country